611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Health Sciences
Resources
Basic InformationLatest News
A Gene Kept One Woman From Developing Alzheimer's -- Could It Help Others?Could AI Beat Radiologists at Spotting Bleeds in the Brain?Pro Soccer Players More Likely to Develop Dementia: StudyExtinct Human Species Passed on Powerful Immune System GeneScientists ID Genes Tied to Left-HandednessScientists Creating Gene Map of Human 'Microbiome'New DNA Blood Test May Help Guide Breast Cancer TreatmentFootball Head Trauma Linked Again to Long-Term Brain DamageMore 'Buyer Beware' Warnings for Unregulated Stem Cell Clinics3-D Printers Might Someday Make Replacement HeartsOne Gene Change 2 Million Years Ago Left Humans Vulnerable to Heart AttackHow to Protect Your DNA for Big Health BenefitsBones Help Black People Keep Facial Aging at BayGene Test Might Someday Gauge Your Heart Attack RiskYour Gut Bacteria Could Affect Your Response to MedsIt's Never Too Late for New Brain CellsSensor-Laden Glove Helps Robotic Hands 'Feel' ObjectsAn Antibiotic Alternative? Using a Virus to Fight BacteriaBrain Sharpens the Hearing of the Blind, Study FindsMind-Reading Tech Could Bring 'Synthetic Speech' to Brain-Damaged PatientsCan Obesity Shrink Your Brain?Will You Get Fat? Genetic Test May TellMagnet 'Zap' to the Brain Might Jumpstart Aging MemoryWhy More Patients Are Surviving an AneurysmIsraeli Team Announces First 3D-Printed Heart Using Human CellsPoverty Could Leave Its Mark on GenesNFL Retirees Help Scientists Develop Early Test for Brain Condition CTEBrain 'Zap' Might Rejuvenate Aging MemoryLab-Grown Blood Vessels Could Be Big Medical AdvanceOnly Spoken Words Processed in Newly Discovered Brain RegionSmall Trial Provides New Hope Against Parkinson's DiseaseInsomnia May Be in Your Genes'Miracle' Young Blood Infusion Treatments Unproven, Potentially Harmful: FDAPossible Parkinson's 'Pandemic' Looms: ReportScience Puzzling Out Differences in Gut Bacteria Around the World'Mind-Reading' AI Turns Thoughts Into Spoken WordsEat What You Want and Still Stay Slim? Thank Your GenesGood News, Bad News on Levodopa for Parkinson's DiseaseNature or Nurture? Twins Study Helps Sort Out Genes' Role in DiseaseBeing Bullied May Alter the Teen BrainFDA Warns Companies on Dangerous, Unapproved Stem Cell TreatmentsGene Tweaking Prevented Obesity in MiceApproach That New Gene Testing Kit With CautionResearch on Almost 2,000 Brains Brings Insight Into Mental IllnessRestoring Hair Growth on Scarred Skin? Mouse Study Could Show the WayParkinson's Gene Therapy Wires New Brain CircuitsNext for Disabling Back Pain? New Discs From Patients' Own CellsSkin 'Glow' Test Might Someday Spot Disease Risk EarlyComputer-Brain Link Helps 'Locked In' People Chat, Surf WebDeep Brain Stimulation May Hold Promise in Alzheimer's
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

A Gene Kept One Woman From Developing Alzheimer's -- Could It Help Others?

HealthDay News
by By Alan Mozes
HealthDay Reporter
Updated: Nov 4th 2019

new article illustration

MONDAY, Nov. 4, 2019 (HealthDay News) -- Could one woman's rare genetic mutation one day have a global impact on dementia risk?

It's possible, say investigators who report on a potentially groundbreaking case of a woman whose genetic mutation staved off dementia for decades, even though her brain had already been damaged by Alzheimer's disease.

While most Alzheimer's cases are not driven by genetic predisposition, one woman in Colombia is among about 1,200 in her country who do face a genetically higher risk for early-onset Alzheimer's.

Why? They all carry the E280A mutation of a gene called Presenilin 1 (PSEN1), which is known to increase the chances for Alzheimer's at a far younger age than usual.

"We identified an individual that was predisposed to develop Alzheimer's in her 40s," noted study author Dr. Joseph Arboleda-Velasquez. He's an assistant professor of ophthalmology with the Schepens Eye Research Institute of Mass Eye and Ear at Harvard Medical School, in Boston.

But, strangely, the woman "remained unimpaired until her 70s," Arboleda-Velasquez added.

The twist: the woman had, in fact, developed clear telltale signs of Alzheimer's in her brain. She just hadn't developed dementia.

For example, while she had fewer neural "tangles" in her brain than is typical for Alzheimer's patients, by the time she hit her 40s she did have the same unusually high level of brain amyloid-beta deposits as her E280A peers. Such deposits are a key signature of Alzheimer's.

So why didn't she develop middle-aged dementia like her peers?

To unravel the mystery, Arboleda-Velasquez and his colleagues ran an in-depth genetic analysis on the woman. And what they found is that she had not just one mutation, but two.

In addition to the E280A mutation, she also carried the so-called "Christchurch" mutation in the APOE3 gene.

But there's more. Not only did she carry the Christchurch mutation, but she had two of them. Some of her E280A peers (about 6%) also carried a single copy of Christchurch. But she was the only one who carried two, the investigators found.

"It is ultra-rare, with an approximate prevalence of less than one in every 200,000 individuals," Arboleda-Velasquez said.

And having one such rare mutation did not appear to be enough. No protection against dementia was linked to only one Christchurch mutation. But as this woman's case suggests, having two such mutations did seem to throw up a shield against Alzheimer's, preserving her ability to remember things and think clearly for a few decades, long after her E280A peers had started experiencing cognitive decline.

"This is the first time a specific patient who carries the [double] mutation has been linked to such a protective benefit," Arboleda-Velasquez noted.

How does it work? It seems that "the mutation puts a block on the cascade of events linking amyloid accumulation to neural [brain cell] death," he explained.

The team did acknowledge that more research will be needed to definitively confirm the Christchurch mutation's impact, and to further explore how this mutation/dementia delay connection truly works.

But, in theory, the incredibly rare experience of this one woman in Colombia could ultimately have profound ramifications for Alzheimer's patients around the world, if "new drugs that mimic the effect of [the] mutation" could be developed, said Arboleda-Velasquez. Rather than stopping Alzheimer's from developing, such drugs would prevent Alzheimer's from causing dementia.

The study was published Nov. 4 in the journal Nature Medicine, and was partly funded by the U.S. National Institutes of Health and the Alzheimer's Association.

Heather Snyder, vice president of medical and scientific relations at the Alzheimer's Association, characterized the findings as "an important discovery."

The insights gleaned from a look at this particular patient's experience are "full of possibilities for increasing our understanding of Alzheimer's disease and all dementia, and advancing potential avenues for treatment," Snyder suggested.

"Understanding what is happening in the brains of people when there appears to be a delay or stopping of the disease progression -- because of this gene form or otherwise -- gives rise to many possibilities for investigating new treatment and risk-reduction opportunities," she added.

At the same time, Snyder cautioned that "more research is needed to understand more thoroughly how genetics impacts Alzheimer's/dementia risk, and to expand and confirm these findings in a larger number of people."

More information

There's more about Alzheimer's disease at the Alzheimer's Association.